Stereotactic Radiosurgery in Treating Patients With Large Brain Metastases

Tumors Metastatic to Brain Clinical Trial

Official title:

Dose Escalation for Larger Brain Metastases: Phase I/II Study

Clinical Trial Details — Status: Suspended

Administrative data

• NCT number: NCT01843413
• Other study ID #: CASE8312
• Status: Suspended
• Phase: N/A
• Start date: July 2, 2013
• Est. completion date: September 2024

Study information

• Verified date: April 2024
• Source: Case Comprehensive Cancer Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This phase I/II trial studies the side effects and the best dose of stereotactic radiosurgery and to see how well it works in treating patients with large brain metastases. Radiosurgery can send x-rays directly to the tumor and cause less damage to normal tissue.

Description:

PRIMARY OBJECTIVES: I. To determine the incidence of acute and long-term toxicities with increasing dose of stereotactic radiosurgery (SRS). (Phase I) II. To determine if local control may be improved with increasing doses of SRS. (Phase II) SECONDARY OBJECTIVES: I. To determine the risk of acute and long-term toxicity with increasing dose of SRS. (Phase II) II. To determine if there is increased neurocognitive toxicity with increased dose of SRS. III. To determine the rate of radiation necrosis/steroid dependency. IV. To determine if quality of life is affected more by tumor recurrence versus radiation necrosis. This includes assessment of progression free survival, overall survival, local failure, and number of patients who receive bevacizumab, laser interstitial thermal therapy, or surgery for presumed radiation necrosis. OUTLINE: This is a phase I dose-escalation study followed by a phase II study. Patients undergo SRS guided by computer tomography (CT) and magnetic resonance imaging (MRI). After completion of treatment, patients are followed up at 1-2, 3, 6, 9, and 12 months, every 3 months for 2 years, and then every 4 months thereafter.

Recruitment information / eligibility

• Status: Suspended
• Enrollment: 40
• Est. completion date: September 2024
• Est. primary completion date: September 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Any patient undergoing SRS for brain metastases
• Lesions to be treated under this protocol must be > 2 cm, but =< 4.0 cm in diameter
• Patients may have had prior therapy including:
• Whole brain radiation therapy (WBRT) > 3 months ago
• SRS to other brain metastases
• Patients with newly diagnosed brain metastases are eligible as long as they are not planned for WBRT upfront
• Any primary is eligible with exception of small cell lung cancer, lymphoma, and germ cell histologies
• Patient must be able to provide written informed consent

Exclusion Criteria:

• Patients receiving SRS to resection bed
• Planned concurrent WBRT
• Leptomeningeal metastases
• Small cell lung cancer, lymphoma, and germ cell histologies
• Inability to participate in study activities due to physical or mental limitations
• Inability or unwillingness to return for all the required follow-up visits
• Conformality index 2.0 or less cannot be achieved, or homogeneity index is > 2.0
• Unable to deliver 10 Gray (Gy) or less to optic nerve/chiasm
• Brainstem location is excluded from this study

Related Conditions & MeSH terms

• Brain Neoplasms
• Tumors Metastatic to Brain
• Unspecified Adult Solid Tumor

Intervention

Radiation:
• stereotactic radiosurgery
Undergo SRS

Procedure:
• quality-of-life assessment
Ancillary studies
• cognitive assessment
Ancillary studies

Locations

Country	Name	City	State
United States	Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center	Cleveland	Ohio

Sponsors (1)

Lead Sponsor	Collaborator
Case Comprehensive Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maximum-tolerated dose based on the incidence of dose-limiting toxicity (DLT) defined as any grade III or IV toxicity as assessed by the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 (Phase I)		Up to 4 months
Primary	Response associated with increased dose of SRS as assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) (Phase II)		Up to 2 years
Secondary	Incidence of adverse events as assessed by CTCAE version 4.0 (Phase II)	Toxicity will be summarized as frequencies and percentages with a corresponding exact 95% confidence interval.	Up to 2 years
Secondary	Quality of life (QOL) as assessed by the Functional Assessment of Cancer Therapy-Brain (FACT-BR) and the European Organization for Research and Treatment (EORTC)- Quality of Life Questionnaire Core 30 (QLQ30)		Up to 12 months